--- title: "BeOne Medicines annual revenue is 38.2 billion: net profit 1.46 billion, Amgen and Baker are core shareholders" type: "News" locale: "en" url: "https://longbridge.com/en/news/282768569.md" description: "Beijing Beion Pharmaceuticals Co., Ltd. (688235) released its 2025 financial report, with annual revenue of 38.225 billion, a year-on-year increase of 40.46%; net profit of 1.461 billion, an improvement compared to a net loss of 4.978 billion in the same period last year. Revenue in the fourth quarter was 10.63 billion, with a net profit of 322 million. During the reporting period, research and development expenses amounted to 15.508 billion, and the net cash flow from operating activities was 13.713 billion. Amgen and Baker Brothers are the core shareholders, holding 17.09% and 8.03% of the shares, respectively" datetime: "2026-04-15T02:00:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282768569.md) - [en](https://longbridge.com/en/news/282768569.md) - [zh-HK](https://longbridge.com/zh-HK/news/282768569.md) --- # BeOne Medicines annual revenue is 38.2 billion: net profit 1.46 billion, Amgen and Baker are core shareholders Leidi News, April 15 Beijing Beion Pharmaceuticals Co., Ltd. (stock code: 688235, abbreviated as Beion Pharmaceuticals) recently released its financial report for the period ending December 31, 2025. The report shows that Beion Pharmaceuticals' revenue for 2025 is 38.225 billion, an increase of 40.46% compared to 27.2 billion in the same period last year; Beion Pharmaceuticals' net profit for 2025 is 1.461 billion, compared to a net loss of 4.978 billion in the same period last year; the net profit after excluding non-recurring items is 1.42 billion, compared to a net loss of 5.379 billion in the same period last year. Beion Pharmaceuticals' revenue for the fourth quarter of 2025 is 10.63 billion, with a net profit of 322 million and a net profit of 450 million after excluding non-recurring items. During the reporting period, Beion Pharmaceuticals' net cash flow from operating activities was 13.713 billion; the total R&D investment for the year was 15.508 billion. Amgen and Baker are core shareholders As of December 31, 2025, Amgen holds 17.09%, Baker Brothers Life Sciences, L.P. and its affiliates hold 8.03%, and Capital Research and Management Company and its affiliates hold 5.37%. Beion Pharmaceuticals' equity structure as of December 31, 2025 As of June 30, 2025, Amgen holds 17.24%, Baker Brothers Life Sciences, L.P. and its affiliates hold 8.1%, Capital Research and Management Company and its affiliates hold 5.88%, and Industrial and Commercial Bank of China Limited - China Europe Medical Health Mixed Securities Investment Fund holds 0.34%; As of March 31, 2025, the equity structure of BeOne Medicines Guangzhou High-tech Zone Technology Holding Group Co., Ltd. holds 0.24%, Bank of Communications Co., Ltd. - WanJia Industry Preferred Mixed Securities Investment Fund (LOF) holds 0.21%, China Construction Bank Co., Ltd. - ICBC Credit Suisse Frontier Medical Equity Securities Investment Fund holds 0.19%; Specifically, Baker Brothers Life Sciences has slightly reduced its holdings. ——————————————— ### Related Stocks - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [BTP.SG](https://longbridge.com/en/quote/BTP.SG.md) - [NDRA.US](https://longbridge.com/en/quote/NDRA.US.md) - [OLSI.US](https://longbridge.com/en/quote/OLSI.US.md) - [NA.US](https://longbridge.com/en/quote/NA.US.md) - [NLY.US](https://longbridge.com/en/quote/NLY.US.md) - [RAND.US](https://longbridge.com/en/quote/RAND.US.md) - [SCU.US](https://longbridge.com/en/quote/SCU.US.md) - [601398.CN](https://longbridge.com/en/quote/601398.CN.md) - [01398.HK](https://longbridge.com/en/quote/01398.HK.md) - [601328.CN](https://longbridge.com/en/quote/601328.CN.md) - [03328.HK](https://longbridge.com/en/quote/03328.HK.md) - [601939.CN](https://longbridge.com/en/quote/601939.CN.md) - [00939.HK](https://longbridge.com/en/quote/00939.HK.md) - [29273B500.US](https://longbridge.com/en/quote/29273B500.US.md) - [NLY-F.US](https://longbridge.com/en/quote/NLY-F.US.md) - [NLY-J.US](https://longbridge.com/en/quote/NLY-J.US.md) - [NLY-I.US](https://longbridge.com/en/quote/NLY-I.US.md) - [NLY-G.US](https://longbridge.com/en/quote/NLY-G.US.md) ## Related News & Research - [Congressional Trading Report: Rep. Maria Elvira Salazar Bought Over $221K In Amgen Stock](https://longbridge.com/en/news/283691683.md) - [AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER | AMGN Stock News](https://longbridge.com/en/news/283715955.md) - [AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS](https://longbridge.com/en/news/284050872.md) - [BeOne Medicines Revamps Board and Committees Ahead of 2026 AGM](https://longbridge.com/en/news/283065000.md) - [Market Chatter: Pfizer, Amgen Eyeing Hong Kong Expansion](https://longbridge.com/en/news/283325185.md)